Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (February 2021)
20 slides from Noxopharm's investor presentation, Feb 23, 2021
Slide 1: ASX Announcement: Noxopharm Updated Corporate Presentation
For personal use only ASX Announcement | 23 February 2021 Noxopharm Limited (ASX:NOX) Noxopharm Updated Corporate Presentation February-March 2021 23 February 2021 Sydney, Australia: Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), provides to shareholders and the mar
Slide 2: Forward Looking Statements
For personal use only Media Enquiries Julia Maguire The Capital Network E: julia@thecapitalnetwork.com.au T: + 61 2 8999 3699 Forward Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”,
Slide 3: Updated Corporate Presentation February/March 2021
For personal use only Noxopharm Limited (ASX:NOX) UPDATED CORPORATE PRESENTATION February/March 2021 Discover Develop Dr Graham Kelly CEO and Managing Director Deliver NOXOPHARM LIMITED (ASX:NOX) 1
Slide 4: Disclaimer
Disclaimer For personal use only This presentaIon has been prepared by Noxopharm Limited (NOX or the Company). It should not Although the Company believes that the expectaIons reflected in the forward looking statements be considered as an offer or invitaIon to subscribe for, or purchase any shares in
Slide 5: Latest News
Latest News For personal use only IONIC TRIAL. IONIC study submi]ed for ethics approval. Trial DARRT-2 TRIAL. Study LuPIN TRIAL. Major expanded into wide range of cancer conference hears expected to commence following paIent screen cancers. Hospital selecIon NOX + Novartis drug for mulInaIonal study
Slide 6: Veyonda breakthrough multiple-acting immunotherapy drug
Veyonda® breakthrough mul5ple-ac5ng For personal use only immunotherapy drug Blocks autophagy AcIvates increasing immune immune cells acIvaIon Inhibits Increases inflammaIon trafficking of activated immune cells Source: Dana-Faber Cancer Institute Converts COLD tumors to HOT tumors NOXOPHARM LIMITED
Slide 7: Veyonda Clinical program
Veyonda® Clinical program For personal use only LuPIN-1 Phase I/II trial Veyonda + 177Lu-PSMA (NovarLs) IONIC-1 Phase I/II trial Veyonda + Opdivo® (Bristol Myers Squibb) DARRT-2 Phase II trial Veyonda + external radiotherapy NOXCOVID-1 Phase Ib trial Veyonda NOXOPHARM LIMITED (ASX:NOX) 5
Slide 8: Short- to medium-term potential partnering opportunities
Short- to medium-term poten1al partnering opportuni1es For personal use only The focus of this presentation LuPIN-1 Phase I/II trial Veyonda + 177Lu-PSMA (NovarLs) IONIC-1 Phase I/II trial Veyonda + Opdivo® (Bristol Myers Squibb) DARRT-2 Phase II trial Veyonda + external radiotherapy NOXCOVID-1 Phas
Slide 9: LuPIN: Veyonda + 177lutetium-PSMA-617
For personal use only LuPIN Veyonda® + 177lutetium-PSMA-617 An exciting new treatment for prostate cancer NOXOPHARM LIMITED (ASX:NOX) 7
Slide 10: LuPIN (Veyonda + Lu-PSMA-617)
LuPIN (Veyonda + Lu-PSMA-617 For personal use only 177luteLum-PSMA-617. Acquired by NovarIs (4th largest pharma company/US$195 billion market cap) in 2018 for US$6 billion Lu-PSMA-617 is a radioacIve drug injected IV and designed to deliver radiaIon to every prostate cancer cell throughout the body
Slide 11: LuPIN Study
LuPIN Study For personal use only QUESTION: would adding Veyonda boost the effecIveness of the NovarIs drug, with more men responding as well as achieving significantly longer survival Imes? Phase I/II study. St Vincent’s Hospital Sydney. Prof Louise Emme] 56 men. Late-stage cancer. No remaining stand
Slide 12: LuPIN: Interim Data Reporting
LuPIN: Interim Data Reporting For personal use only American Society of Clinical Oncology Genitourinary Cancers Symposium Feb 11-13 2021 ANSWER: Yes, the combination of Veyonda and Lu-PSMA-617 looks to considerably more effective than Lu-PSMA-617 on its own (based on published Phase 2 data1) 56 men
Slide 13: LuPIN: Interim Survival Data
LuPIN: Interim Survival Data For personal use only Median overall survival = time when half the patients have died and half still alive Three standard lines of drug therapy once prostate 1st line 2nd line 3rd line End-stage cancer becomes metastaIc Historical data1 ~ 4.5 months 177 Lu-PSMA-617 alone
Slide 14: Potential opportunities for LuPIN
Poten5al opportuni5es for LuPIN For personal use only LuPIN Study Three standard lines of drug therapy once prostate 1st line 2nd line 3rd line End-stage cancer becomes metastaIc VISION Study NovarIs preferred treatment opIons1 1. NovarIs Oncology Pipeline Update June 2020 NOXOPHARM LIMITED (ASX:NOX
Slide 15: IONIC: Veyonda + nivolumab (Opdivo)
For personal use only IONIC Veyonda ® + nivolumab (Opdivo®) Overcoming resistance to checkpoint inhibitors NOXOPHARM LIMITED (ASX:NOX) 13
Slide 16: IONIC Study Phase I/II pilot proof-of-concept study
IONIC Study Phase I/II pilot proof-of-concept study For personal use only 15 patients treated with 15 patients with cancers Opdivo where tumours considered resistant to Opdivo not responsive • Melanoma All other cancer types • Lung • Kidney Typically 0-3% response rate • Bladder • Head & neck Veyond
Slide 17: Other Updates
OTHER UPDATES For personal use only DARRT-2 trial SelecIon of clinical sites almost completed. LuPIN trial Study ends Oct 2021. Final Report expected Q1 2022 NOXCOVID trial Part 2 to start 1st March 2021. Drug pipeline First-in-class drug with novel approach to treatment of brain cancer progressing
Slide 18: Our commercial end-point for Veyonda
Our commercial end-point for Veyonda For personal use only A number of important blockbuster (>US$1 B annual sales) drugs are losing their exclusivity over coming years. This is putting pressure on big pharma to refresh revenue streams through M&A activity Programs focusing on immuno-oncology and ce
Slide 19: Key metrics
Key metrics For personal use only as at 19 February 2021 Market cap A$210m News Flow (next 6 months) • IONIC-1 and DARRT-2 start paIent recruitment Share price A$0.79 • COVID-19 clinical trial compleIon • Growing first-in-class drug pipeline Issued cap ~266m shares • Pharmorage (subsidiary) progressi
Slide 20: For further information
For personal use only For further informa.on email: info@noxopharm.com web: www.noxopharm.com twi\er: @noxopharm Discover Develop Deliver NOXOPHARM LIMITED (ASX:NOX) 18